NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab

Biomedicine and Pharmacotherapy

Volumn 63, Issue 6, 2009, Pages 413-420

  Markasz, Laszlo ^a   Vanherberghen, Bruno ^a   Flaberg, Emilie ^a   Ötvös, Rita ^a   Stuber, Gyorgy ^a   Gustafsson Jernberg, Åsa ^b   Olah, Eva ^c   Skribek, Henriette ^a   Szekely, Laszlo ^a  

^a Center for Integrative Recognition in the Immune System   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Complement; Killing; LCL; NK cells; PTLD; Rituximab

Indexed keywords

CD20 ANTIGEN; COMPLEMENT; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL TRANSFORMATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FLUORESCENCE MICROSCOPY; HEATING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HOT TEMPERATURE; HUMANS; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; MICROSCOPY, CONFOCAL; PLASMA;

EID: 68649101232     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.08.009     Document Type: Article

References (58)

1. Grillo-Lopez A.J., White C.A., Varns C., Shen D., Wei A., McClure A., et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26 5 Suppl. 14 (1999) 66-73
2. Eisenberg R. Update on rituximab. Ann Rheum Dis 64 Suppl(4) (2005) 55-57
3. Kehrl J.H., Riva A., Wilson G.L., et al. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 15 9 (1994) 432-436
4. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15 9 (1994) 450-454
5. Riley J.K., and Sliwkowski M.X. CD20: a gene in search of a function. Semin Oncol 27 6 Suppl. 12 (2000) 17-24
6. Jazirehi A.R., Huerta-Yepez S., Cheng G., and Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65 1 (2005) 264-276
7. Jazirehi A.R., Vega M.I., Chatterjee D., Goodglick L., and Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 64 19 (2004) 7117-7126
8. Suzuki E., Umezawa K., and Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 26 42 (2007) 6184-6193
9. Vega M.I., Huerta-Yepaz S., Garban H., Jazirehi A., Emmanouilides C., and Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 23 20 (2004) 3530-3540
10. O'Keefe T.L., Williams G.T., Davies S.L., and Neuberger M.S. Mice carrying a CD20 gene disruption. Immunogenetics 48 2 (1998) 125-132
11. Hofmeister J.K., Cooney D., and Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26 2 (2000) 133-143
12. Maloney D.G. Rituximab for follicular lymphoma. Curr Hematol Rep 2 1 (2003) 13-22
13. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22 47 (2003) 7359-7368
14. Shan D., Ledbetter J.A., and Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91 5 (1998) 1644-1652
15. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 12 (2000) 3900-3908
16. Teeling J.L., French R.R., Cragg M.S., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 6 (2004) 1793-1800
17. Flieger D., Renoth S., Beier I., Sauerbruch T., and Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 204 1 (2000) 55-63
18. Harjunpaa A., Junnikkala S., and Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51 6 (2000) 634-641
19. Bellosillo B., Villamor N., Lopez-Guillermo A., Marce S., Esteve J., Campo E., et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98 9 (2001) 2771-2777
20. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 12 (2001) 3383-3389
21. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101 3 (2003) 949-954
22. Fischer L., Penack O., Gentilini C., Nogai A., Muessig A., Thiel E., et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 34 6 (2006) 753-759
23. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 3 (2002) 754-758
24. Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D., and Byrd J.C. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103 4 (2004) 1472-1474
25. Bower M. The management of lymphoma in the immunosuppressed patient. Best Pract Res Clin Haematol 15 3 (2002) 517-532
26. Curtis R.E., Travis L.B., Rowlings P.A., Socie G., Kingma D.W., Banks P.M., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94 7 (1999) 2208-2216
27. Gross T.G., Steinbuch M., DeFor T., Shapiro R.S., McGlave P., Ramsay N.K., et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 23 3 (1999) 251-258
28. Zutter M.M., Martin P.J., Sale G.E., Shulman H.M., Fisher L., Thomas E.D., et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72 2 (1988) 520-529
29. Gustafsson A., Levitsky V., Zou J.Z., Frisan T., Dalianis T., Ljungman P., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95 3 (2000) 807-814
30. Armitage J.M., Kormos R.L., Stuart R.S., Fricker F.J., Griffith B.P., Nalesnik M., et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 10 6 (1991) 877-886 discussion 886-7
31. Leblond V., Sutton L., Dorent R., Davi F., Bitker M.O., Gabarre J., et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 13 4 (1995) 961-968
32. Opelz G., and Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 2 (2004) 222-230
33. Milpied N., Vasseur B., Parquet N., Garnier J.L., Antoine C., Quartier P., et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 Suppl 1 (2000) 113-116
34. Savoldo B., Goss J., Liu Z., Huls M.H., Doster S., Gee A.P., et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72 6 (2001) 1078-1086
35. Lacerda J.F., Ladanyi M., Louie D.C., Fernandez J.M., Papadopoulos E.B., and O'Reilly R.J. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med 183 3 (1996) 1215-1228
36. Rowe M., Young L.S., Crocker J., Stokes H., Henderson S., and Rickinson A.B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173 1 (1991) 147-158
37. Lazzarino M., Arcaini L., Orlandi E., Iacona I., Bernasconi P., Calatroni S., et al. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology 68 2-3 (2005) 146-153
38. Markasz L., Stuber G., Flaberg E., Gustafsson Jernberg A., Eksborg S., Olah E., et al. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B cells. BMC Cancer 6 1 (2006) 265
39. Markasz L., Stuber G., Vanherberghen B., Carbone E., Flaberg E., Eksborg S., et al. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human NK cells. Mol Cancer Ther 6 2 (2007) 644-654
40. Dunne J., Lynch S., O'Farrelly C., Todryk S., Hegarty J.E., Feighery C., et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 167 6 (2001) 3129-3138
41. Phillips J.H., and Lanier L.L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164 3 (1986) 814-825
42. Gluck W.L., Hurst D., Yuen A., Levine A.M., Dayton M.A., Gockerman J.P., et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10 7 (2004) 2253-2264
43. Nichols K.E., Ma C.S., Cannons J.L., Schwartzberg P.L., and Tangye S.G. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 203 (2005) 180-199
44. Sharifi R., Sinclair J.C., Gilmour K.C., Arkwright P.D., Kinnon C., Thrasher A.J., et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 103 10 (2004) 3821-3827
45. Gelderman K.A., Tomlinson S., Ross G.D., and Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25 3 (2004) 158-164
46. Erdei A., Benczur M., Fabry Z., Dierich M.P., and Gergely J. C3 cleaved by membrane proteases binds to C3b acceptors expressed on concanavalin A-stimulated human lymphocytes and enhances antibody-dependent cellular cytotoxicity. Scand J Immunol 20 2 (1984) 125-131
47. Ramos O.F., Sarmay G., Klein E., Yefenof E., and Gergely J. Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. Proc Natl Acad Sci U S A 82 16 (1985) 5470-5474
48. Perlmann H., Perlmann P., Schreiber R.D., and Muller-Eberhard H.J. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med 153 6 (1981) 1592-1603
49. Wahlin B., Perlmann H., Perlmann P., Schreiber R.D., and Muller-Eberhard H.J. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. J Immunol 130 6 (1983) 2831-2836
50. Vetvicka V., Hanikyrova M., Vetvickova J., and Ross G.D. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Clin Exp Immunol 115 2 (1999) 229-235
51. Ayache S., Panelli M.C., Byrne K.M., Slezak S., Leitman S.F., Marincola F.M., et al. Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. J Transl Med 4 2 (2006) 40
52. Linscott W.D., and Triglia R.P. The bovine complement system. Adv Exp Med Biol 137 (1981) 413-430
53. Kennedy A.D., Solga M.D., Schuman T.A., Chi A.W., Lindorfer M.A., Sutherland W.M., et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101 3 (2003) 1071-1079
54. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61 13 (2001) 5137-5144
55. Ghetie M.A., Bright H., and Vitetta E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97 5 (2001) 1392-1398
56. Jazirehi A.R., Gan X.H., De Vos S., Emmanouilides C., and Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2 11 (2003) 1183-1193
57. Katz P., Zaytoun A.M., and Lee Jr. J.H. Mechanisms of human cell-mediated cytotoxicity. III. Dependence of natural killing on microtubule and microfilament integrity. J Immunol 129 6 (1982) 2816-2825
58. Ujhazy P., and Babusikova O. NK-cell activity affected by some cytostatic drugs and their additives. Neoplasma 38 3 (1991) 303-312